Browsing by Subject/keywords Follow Up

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
PreviewIssue DateTitle / NameAuthor(s)Type
J of Gastro and Hepatol - 2015 -  - Gastrointestinal Cancer.pdf.jpg2015A regional experience of the national bowel cancer screening programVaughan, R.; Versace, Vincent L.; Morphett, B.Journal Article 
2022CDK4/6 Inhibitors (CKD4/6i) in advanced hormone-receptor-positive (HR+) HER2-negative (HER2-) breast cancer: Prescribing practices and outcomes in a real-world, Australian cohortJavaid, Anadil; Lok, Sheau Wen; Wong, Vanessa; Baron-Hay, Sally; Boyle, Fran, et alConference Paper 
2006Component separation in the repair of a giant inguinoscrotal herniaEk, Edmund W.; Ek, Eugene T.; Bingham, Roger; Wilson, Jeremy; Mooney, Brendan, et alJournal Article 
2018Management of brainmetastases in patients with HER2 positive breast cancer-a real world Australian experienceMoldovan, Cristina A.; King, Rossa; Lok, Sheau Wen; De Boer, Richard; Gibbs, Peter, et alConference Paper 
2019Management of neuroendocrine tumours in metropolitan and regional South West VictoriaDean, Samantha L.; Hayes, Theresa M.; Rogers, Margaret J.; Versace, Vincent; Collins, Ian M., et alConference Paper 
2021MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum SensitivitySpigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et alConference Paper 
2019OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung CancerPaz-Ares Rodriguez, L.; Spigel, David R.; Chen, Yuanbin; Jove, Maria; Juan, O., et alConference Paper 
2021P48.14 RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line SettingPaz-Ares, Luis; Spigel, David R.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et alConference Paper 
2020RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivitySpigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et alConference Paper 
2020RESILIENT part II: An open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapySpigel, David R.; Paz-Ares, Luis G.; Moore, Yan; Zhang, Bin; Dowlati, Afshin, et alConference Paper